middle.news
Neuren’s DAYBUE Royalties Climb 16% as Patient Numbers Hit Record High
10:01am on Thursday 7th of August, 2025 AEST
•
Pharmaceuticals
Read Story
Neuren’s DAYBUE Royalties Climb 16% as Patient Numbers Hit Record High
10:01am on Thursday 7th of August, 2025 AEST
Key Points
Q2 2025 DAYBUE net sales up 14% year-on-year to US$96.1 million
Neuren’s Q2 royalty income rises 16% to A$14.7 million
Record 987 unique patients treated in the US, growing for third consecutive quarter
Acadia expands DAYBUE sales force by ~30% to boost community penetration
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE